Dermata Therapeutics Inc. (DRMAW)
0.02
-0.01 (-31.03%)
At close: Jan 28, 2025, 1:56 PM
0.02
0.00%
After-hours Jan 28, 2025, 01:56 PM EST
Company Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions.
The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea.
It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions.
The company was founded in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gerald T. Proehl |
Contact Details
Address: 3525 Del Mar Heights Road San Diego, California United States | |
| Website | http://www.dermatarx.com |
Stock Details
| Ticker Symbol | DRMAW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001853816 |
| CUSIP Number | 249845116 |
| ISIN Number | US2498451168 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer & Chairman |
| Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President & Chief Financial Officer |
| David F. Hale | Co-Founder & Lead Independent Director |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President & Chief Development Officer |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Sean Proehl | Senior Director of Legal & Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 23, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jan 23, 2025 | 4 | Filing |
| Jan 23, 2025 | 4 | Filing |
| Jan 23, 2025 | 4 | Filing |
| Jan 23, 2025 | 4 | Filing |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |